Potentiality of Bacteriocins as the Attachment Inhibitors of HIV-1 gp120

Abstract

It is postulated that some bacteriocin derivatives are consummate candidates to inhibit the binding of HIV gp120 to CD4 T-cell. From the discovery of bacteriocin compounds in 1925 and forth, nearly 300 bacteriocins have been identified. Of various bacteriocins, there are some which have been used successfully for inhibiting both animal and human pathogens. Unfortunately, no large extent research has been found in the development of various bacteriocins as HIV entry inhibitor. Therefore, we need to initiate to hunt for potential bacteriocins that prevent viral entry to T-cells and protect HIV victims. In this current study, we have proposed the static approach to categorize 177 bacteriocins into several distinguishing molecular descriptor (MD) families according to their structures (amino acid sequences) and inhibition capacity of HIV entry by utilizing the second released database tool of BACTIBASE. This process of classification will reduce our time to search for appropriate bacteriocins with best inhibition capacity of HIV entry. We have proposed the methodologies to test this representative class further in vitro and in silico. The main advantage of bacteriocin compounds is that we are able to design them in various formulations, such as, capsule, tablet, dry powder for suspension, etc., and prescribe them orally like antibiotics. As entry inhibitors (EIs), the potential bacteriocins are suitable ingredients to prepare vaginal/rectal gels, creams, pills and intravaginal ring systems. Not only that, the bacterial strains that produce omnipotent bacteriocins can be used as a human vaginal/rectal/oral probiotic strains which can potentially lower the sexual transmission of HIV.

Keywords: Bacteriocin derivatives, HIV entry inhibitors, BACTIBASE, in vitro and
in silico test

Cite this Article

SK. Md. Mujahidy Jakaria. Potentiality of Bacteriocins as the Attachment Inhibitors of HIV-1 gp120. Research & Reviews: Journal of Microbiology and Virology. 2015; 5(3): 18–23p.